دورية أكاديمية
Clinical relevance of high plasma trough levels of the kinase inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC patients
| العنوان: | Clinical relevance of high plasma trough levels of the kinase inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC patients |
|---|---|
| المؤلفون: | Lin, L.S., Barkman, H.J., Smit, E.F., Langen, A.J. de, Steeghs, N., Beijnen, J.H., Huitema, A.D.R. |
| المصدر: | Therapeutic Drug Monitoring |
| سنة النشر: | 2024 |
| المجموعة: | Leiden Repository (Leiden University) |
| مصطلحات موضوعية: | non-small-cell lung cancer, kinase inhibitors, toxicity, adverse events, therapeutic drug monitoring |
| الوصف: | Background:the study aims to evaluate whether high plasma trough levels of the kinase inhibitors (K.I.s) crizotinib, alectinib, osimertinib, dabrafenib, and trametinib were associated with a higher risk of toxicity in non-small-cell lung cancer patients.Methods:In this retrospective cohort study, patients with non-small-cell lung cancer treated with the selected K.I.s were included if at least one plasma trough level at steady state (Cmin,ss) was available. Data were extracted from electronic medical records and laboratory databases. The high group for each K.I. was defined as 10% of patients with the highest first Cmin,ss. The remaining patients were placed in the non-high group. The frequency of dose-limiting toxicities (DLTs), defined as adverse events leading to dose reduction, dose interruption, or permanent discontinuation, was compared between the 2 groups.Results:A total of 542 patients were included in the different K.I. groups. A high Cmin,ss of crizotinib (n = 96), alectinib (n = 105), osimertinib (n = 227), dabrafenib (n = 52), and trametinib (n = 62) correlated with a Cmin,ss >= 490, >= 870, >= 405, >= 150, and >= 25 ng/mL, respectively. DLTs were more common in the alectinib high group than in the alectinib non-high group (64% vs. 29%, P = 0.036). Liver toxicity was observed in 4 (36%) patients in the high group and 5 (5%) patients in the non-high group (P = 0.007). For other K.I.s, no significant differences were observed in the frequency of DLTs between the high and non-high groups.Conclusions:For alectinib, high Cmin,ss was correlated with a higher risk of DLT. No differences in the frequency of DLTs were observed between the high and non-high groups for crizotinib, osimertinib, dabrafenib, and trametinib. ; Pathogenesis and treatment of chronic pulmonary diseases |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | lumc-id: 186083128; https://hdl.handle.net/1887/3720877Test |
| DOI: | 10.1097/FTD.0000000000001120 |
| الإتاحة: | https://doi.org/10.1097/FTD.0000000000001120Test https://hdl.handle.net/1887/3720877Test |
| رقم الانضمام: | edsbas.630CAE6D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/FTD.0000000000001120 |
|---|